Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Quantum Biopharma Ltd. - Class B Subordinate Voting Shares
(NQ:
QNTM
)
6.910
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Quantum Biopharma Ltd. - Class B Subordinate Voting Shares
< Previous
1
2
3
Next >
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Appoints Anti-Corruption Advocate Kevin Malone as Board Advisor
April 24, 2025
Via
Investor Brand Network
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time
April 24, 2025
From
Quantum BioPharma
Via
GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Appoints Anti-Corruption Advocate Kevin Malone as Board Advisor
April 22, 2025
Via
Investor Brand Network
Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor
April 22, 2025
From
Quantum BioPharma
Via
GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Issues Corporate Update
April 21, 2025
Via
Investor Brand Network
Silver Linings Developing Underneath Market Surface; One New Swing Trade For Monday $SPY $QQQ
April 17, 2025
In this video lesson, I look at the overall market, what I expect the market to do in the intermediate term, my game plan per all my time frames and accounts.
Via
Talk Markets
Topics
Stocks / Equities
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Prevails in Legal Dispute With Former CEO
April 14, 2025
Via
Investor Brand Network
Topics
Bonds
Exposures
Debt Markets
Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario
April 14, 2025
Awards in favour of Quantum BioPharma Totalling $180,000 upheld and is now due
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Expands Reach of unbuzzd Through AATAC Retail Deal
April 10, 2025
Via
Investor Brand Network
Quantum BioPharma Licensee Celly Nutrition Announces Landmark Partnership with the Asian American Trade Associations Council (AATAC) to Expand Retail Availability of its Alcohol Detox Beverage unbuzzd™
April 10, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Launches Alcohol-Metabolism Beverage in Puerto Rico
April 03, 2025
Via
Investor Brand Network
Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico
April 03, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Partners with Mass General on PET Imaging Study for Multiple Sclerosis
April 01, 2025
Via
Investor Brand Network
Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis
April 01, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Closes $5 Million Offering to Advance Drug Development
March 31, 2025
Via
Investor Brand Network
Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms
March 31, 2025
From
Quantum BioPharma
Via
GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports Q4 and Full-Year 2024 Financial Results, Highlights Breakthroughs in Alcohol Detox and MS Treatments
March 28, 2025
Via
Investor Brand Network
Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
March 28, 2025
Via
ACCESS Newswire
Quantum Biopharma’s 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
March 28, 2025
Completion of unbuzzd™ Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company’s Pipeline of Products and Assets
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Appoints Terry Lynch to Board, Grants Options
March 27, 2025
Via
Investor Brand Network
Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors
March 27, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Stock Soars After Licensee Celly Nutrition Releases New Format Of Alcohol Detox Product – Retail Shrugs It Off
March 26, 2025
Celly Nutrition has to pay 7% royalty on sales of alcohol detox product unbuzzd to Quantum until payments total $250 million and 3% royalty afterwards.
Via
Stocktwits
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Launches Retail-Ready unbuzzd Stick Packs Across U.S. Stores
March 26, 2025
Via
Investor Brand Network
Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail Sales
March 26, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
March 20, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Let's have a look at the top gainers and losers in the middle of the day of today's session.
March 17, 2025
Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
What's going on in today's after hours session
March 14, 2025
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Completes Phase 1 Trial for MS Treatment, Reports Positive Safety Results
February 26, 2025
Via
Investor Brand Network
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302
February 26, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Continues to Diversify its Treasury with the Purchase of Another USD $1,000,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
February 18, 2025
From
Quantum BioPharma
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.